tbuckley/cabot-search huggingface dataset:
THE TYPHOID SPINE.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Impact of the Stress Hyperglycemia Ratio on Short-term and Long-term Poor Prognosis in Patients With Acute Coronary Syndrome: Insight From a Large Cohort Study in Asia
Authors: Jie Yang, Yitian Zheng, Chen Li, Jun Gao, Xiangbin Meng, Kuo Zhang, Wenyao Wang, Chunli Shao, Yi-Da Tang
Journal: Diabetes Care (2022)

In recent years, some studies have indicated that a novel marker described as the stress hyperglycemia ratio (SHR) can reflect true acute hyperglycemic status and is associated with the short-term poor prognosis in patients with acute myocardial infarction. In the current study we evaluated the association of SHR with adverse cardiovascular events among patients with acute coronary syndrome (ACS).We consecutively enrolled 5,562 ACS patients who underwent drug-eluting stent (DES) implantation. All subjects were divided into five groups according to SHR, which was determined by the following formula: ABG / [(28.7 × HbA1c %) - 46.7], where ABG is admission blood glucose level. The primary end point was major adverse cardiovascular and cerebrovascular events (MACCE) at the 2-year follow-up, and the secondary end point included major adverse cardiovascular events (MACE) at 2-year follow-up, cardiac death, and nonfatal myocardial infarction (MI) at 2-year follow-up and in-hospital cardiac death and nonfatal MI.A total of 643 MACCE were recorded during a median follow-up of 28.3 months. Kaplan-Meier survival analysis showed the lowest MACCE incidence in quintile 3 (P < 0.001). Moreover, the outcomes of restricted cubic spline analysis suggested that there was a U-shaped or J-shaped association between the SHR and early and late cardiovascular outcomes even after adjustment for other confounding factors.There were U-shaped associations of SHR with MACCE rate and MACE rate at 2-year follow-ups and J-shaped associations of SHR with in-hospital cardiac death and MI and that at 2-year follow-up in ACS patients who underwent DES implantation, and the inflection point of SHR for poor prognosis was 0.78.
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
Authors: Choong-kun Lee, Ho Kyoung Hwang, Hei-Cheul Jeung, Hongjae Chon, Hyung Soon Park, Min Hwan Kim, Mi-Suk Park, Chang Moo Kang, Hye Jin Choi
Journal: Journal of Clinical Oncology (2022)

TPS624 Background: Within the next decade, pancreatic ductal adenocarcinoma (PDAC) is expected to rise to the second leading cause of cancer-related mortality. To increase the survival, various peri-operative treatments have been tested, and adjuvant FOLFIRINOX or gemcitabine plus capecitabine is now standard of care after surgical resection for localized PDAC. Even with superior survival among various disease extent of PDAC, resectable PDAC still shows poor outcomes with surgery followed by adjuvant chemotherapy. This phase II study is investigating the role of modified-FOLFIRINOX as neoadjuvant treatment for resectable PDAC. Methods: This study is a phase II, multi-institutional, single-arm trial to evaluate the efficacy and safety of modified-FOLFIRINOX in resectable PDAC. The main inclusion criteria are histologically confirmed PDAC; resectable PDAC confirmed by both computed tomography (CT) and magnetic resonance imaging (MRI) according to NCCN guideline resectability criteria (no arterial tumor contact to celiac axis, SMA or CHA; no tumor contact with SMV or PV or ≤180° contact without vein contour irregularity); no previous treatment (surgery or chemotherapy); ECOG 0 or 1; and adequate organ function. Patients receive oxaliplatin 85 mg/m 2 D1 + leucovorin 400mg/m 2 D1 + irinotecan 150 mg/m 2 D1 + 5-FU 2,000 mg/m 2 46h continuous infusion, every other week for 6 cycles (12 weeks). Response assessments are performed every 6 weeks using the RECIST criteria version 1.1. Baseline MRI, PET-CT scan before treatment, and pre-surgery MRI after 6 cycles are mandatory. The primary endpoint was R0 resection rate. Secondary endpoints included progression-free survival, overall survival, disease-free survival, objective response rate, safety, resection rate, and correlative biomarker exploration. The study will enroll up to 27 patients and is currently recruiting at four sites in South Korea. As of September 2021, 20 patients have been enrolled. Clinical trial information: KCT0004421 (Registration ongoing for clinicaltrials.gov).
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies
Authors: Daniela Heidenreich, Eleonore Hansen, Sebastian Kreil, Florian Nolte, Mohamad Jawhar, Anna Hecht, Wolf‐Karsten Hofmann, Stefan A. Klein
Journal: American Journal of Hematology (2022)

Abstract Central venous catheters (CVC) placed either via the internal jugular vein (IJV) or the subclavian vein (SCV) are routinely used in patients with hematologic malignancies. In this retrospective study, we systematically compared CVC‐associated complications for both insertion sites, IJV and SCV. Between January 2011 and June 2013, all consecutive patients ( n = 87) were included with at least one CVC ( n = 153; n = 94 IJV; n = 59 SCV) at our institution due to induction/consolidation for AML/ALL or autologous hematopoietic cell transplantation (HCT). Primary study endpoints were central line‐associated (CLABSI), catheter‐related (CRBSI) blood stream infections and local inflammation (LI) at the insertion site. CRBSI occurred earlier and more frequently in the IJV‐ versus the SCV‐group with an incidence rate of CRBSI at day 15 of 10% versus 0% ( p = .04) and a rate of CRBSI per 1000 CVC days of 5.7 versus 1.2. In addition, CLABSI was detected more often in IJV‐ compared to SCV‐CVC (26% vs. 8%, p = .009). Conversely, LI occurred more frequently and earlier in SCV‐ versus IJV‐CVC (88% vs. 56%, p &lt; .0001) with a median time to LI of 9 versus 14 days ( p &lt; .0001). The strongest risk factor for the endpoints CRBSI, CLABSI, and LI was the insertion site. However, SCV insertion was a risk factor for LI ( p = .001, HR: 2.0), insertion in the IJV a risk factor for CLABSI ( p = .044, HR: 2.7) and CRBSI ( p = .036, HR: 5.4). These results demonstrate a differential effect of the insertion site of CVC in neutropenic patients with a significantly reduced frequency of CVC‐related blood stream infections in SCV‐CVC.
Regional myocardial nitric oxide synthase 3 gene transfer reduces tissue-specific consequences of anti adenoviral immune response Zsolt Szelid, Peter Sinnaeve, Hilde Gillijns, Marijke Pellens, Veerle Laurysens, Natascha Van Pelt, Pieter Vermeersch, Anton-Jan Van Zonneveld, Erik Verbeken, Desire Collen, Stefan Janssens. Center for Transgene Technology and Gene Therapy, University of Leuven, Leuven, Belgium
Journal: Journal of the American College of Cardiology (2001)
TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures
Authors: Ricardo A. Chaurio, Carmen M. Anadon, Tara Lee Costich, Kyle K. Payne, Subir Biswas, Carly M. Harro, Carlos Moran, Antonio C. Ortiz, Carla Cortina, Kristen E. Rigolizzo, Kimberly B. Sprenger, Jessica A. Mine, Patrick Innamarato, Gunjan Mandal, John J. Powers, Alexandra Martin, Zhitao Wang, Sumit Mehta, Bradford A. Perez, Roger Li, John Robinson, Jodi L. Kroeger, Tyler J. Curiel, Xiaoqing Yu, Paulo C. Rodriguez, Jose R. Conejo-Garcia
Journal: Immunity (2022)

The immune checkpoint receptor PD-1 on T follicular helper (Tfh) cells promotes Tfh:B cell interactions and appropriate positioning within tissues. Here, we examined the impact of regulation of PD-1 expression by the genomic organizer SATB1 on Tfh cell differentiation. Vaccination of CD4CreSatb1f/f mice enriched for antigen-specific Tfh cells, and TGF-β-mediated repression of SATB1 enhanced Tfh differentiation of human T cells. Mechanistically, high Icos expression in Satb1-/- CD4+ T cells promoted Tfh cell differentiation by preventing T follicular regulatory cell skewing and resulted in increased isotype-switched B cell responses in vivo. Ovarian tumors in CD4CreSatb1f/f mice accumulated tumor antigen-specific, LIGHT+CXCL13+IL-21+ Tfh cells and tertiary lymphoid structures (TLS). TLS formation decreased tumor growth in a CD4+ T cell and CXCL13-dependent manner. The transfer of Tfh cells, but not naive CD4+ T cells, induced TLS at tumor beds and decreased tumor growth. Thus, TGF-β-mediated silencing of Satb1 licenses Tfh cell differentiation, providing insight into the genesis of TLS within tumors.
Riding the coronacoaster of uncertainty
Authors: None The Lancet Infectious Diseases
Journal: The Lancet Infectious Diseases (2020)

Among all the reports, modelling, and desktop exercises in the past decade devoted to preparing for the next pandemic, when COVID-19 spread worldwide, some of the consequences had surely never been predicted. Scientists who were barely known outside a narrow academic circle are now household names, lauded and vilified in turn in the press and on social media. Twitter subscribers who until a few months ago were apparently experts in European relations or constitutional law are now skilled infectious diseases epidemiologists.
Undergraduate Medical Education
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GEOGRAPHIC AND STATISTIC METHODS AS AUXILLARY FACTORS IN THE STUDY OF CARCINOMA.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diphtheria
Authors: G. Bottomley
Journal: BMJ (1859)

exciting c ause of irregular recuirrenice, all trace. of periodicity is lost.Tlhe patienit (loes not kIow wlihen to expect hiis attack.le imaiiy have o01) in a twelvemoiti.lie mnay ha.Uvo onDe to-mor- row, he may hlave four in a moultlh, h-e miiay go Years without one; it may never occur at two intervals alike, an:d when it dloes occur he is perfectly at a loss to saty wvhy it shoul(d choose that particuilar period.T'lhe timiie of its re,currence and its frequiency are alike inexplicable.He may be living in perfect hlaldh andi daily diread.To express suininaiiliv, tfle, -what appear to lbe the facts wvith regard to thie period iity of asthmia, wve may sa-- L. That asthmia is typically periodic.2. That, though there is a period( for each calse, there is no particuilar period for thie disease in gnernal.3. That the Peri(licity of' asthnna is of two kin(ds, intrinsic and extrinsic, the latter a spr.urious pelioclicity, dependent orn the peliodic oeci-ee of the exciting cauSe; the fornier, the true essential periolicity.independent of a:l external circum-l- stances.
THE SELECTIVE SERVICE APPLIED TO PHYSICIANS
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-5: Drug-Eluting Stents for the Treatment of Chronic Total Occlusion: A Comparison with Sirolimus, Paclitaxel, Zotarolimus (Endeavor Resolute), BiolimusA9, EPC Capture and Everolimus-Eluting Stent: Multicenter Registry in Asia
Journal: Journal of the American College of Cardiology (2011)
Assessment of Clinical Palliative Care Trigger Status vs Actual Needs Among Critically Ill Patients and Their Family Members
Authors: Christopher E. Cox, Deepshikha Charan Ashana, Krista L. Haines, David Casarett, Maren K. Olsen, Alice Parish, Yasmin Ali O’Keefe, Mashael Al-Hegelan, Robert W. Harrison, Colleen Naglee, Jason N. Katz, Allie Frear, Elias H. Pratt, Jessie Gu, Isaretta L. Riley, Shirley Otis-Green, Kimberly S. Johnson, Sharron L. Docherty
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Palliative care consultations in intensive care units (ICUs) are increasingly prompted by clinical characteristics associated with mortality or resource utilization. However, it is not known whether these triggers reflect actual palliative care needs. <h3>Objective</h3> To compare unmet needs by clinical palliative care trigger status (present vs absent). <h3>Design, Setting, and Participants</h3> This prospective cohort study was conducted in 6 adult medical and surgical ICUs in academic and community hospitals in North Carolina between January 2019 and September 2020. Participants were consecutive patients receiving mechanical ventilation and their family members. <h3>Exposure</h3> Presence of any of 9 common clinical palliative care triggers. <h3>Main Outcomes and Measures</h3> The primary outcome was the Needs at the End-of-Life Screening Tool (NEST) score (range, 0-130, with higher scores reflecting greater need), which was completed after 3 days of ICU care. Trigger status performance in identifying serious need (NEST score ≥30) was assessed using sensitivity, specificity, positive and negative likelihood ratios, and C statistics. <h3>Results</h3> Surveys were completed by 257 of 360 family members of patients (71.4% of the potentially eligible patient–family member dyads approached) with a median age of 54.0 years (IQR, 44-62 years); 197 family members (76.7%) were female, and 83 (32.3%) were Black. The median age of patients was 58.0 years (IQR, 46-68 years); 126 patients (49.0%) were female, and 88 (33.5%) were Black. There was no difference in median NEST score between participants with a trigger present (45%) and those with a trigger absent (55%) (21.0; IQR, 12.0-37.0 vs 22.5; IQR, 12.0-39.0;<i>P</i> = .52). Trigger presence was associated with poor sensitivity (45%; 95% CI, 34%-55%), specificity (55%; 95% CI, 48%-63%), positive likelihood ratio (1.0; 95% CI, 0.7-1.3), negative likelihood ratio (1.0; 95% CI, 0.8-1.2), and C statistic (0.50; 95% CI, 0.44-0.57). <h3>Conclusions and Relevance</h3> In this cohort study, clinical palliative care trigger status was not associated with palliative care needs and no better than chance at identifying the most serious needs, which raises questions about an increasingly common clinical practice. Focusing care delivery on directly measured needs may represent a more person-centered alternative.
Low incidence of myocardial infarction in the BEST heart failure study Stephen S. Gottlieb, Christopher O'Connor, Peter E. Carson, Jonathan F. Plehn, Michel White, Inder Anand, Marc Silver, Jeffrey L. Anderson, Heidi Krause-Steinrauf, for the BEST Investigators. University of Maryland, Baltimore, MD
Journal: Journal of the American College of Cardiology (2001)
Hoematoxylon Dissolved in Dimethylsulfoxide (D.M.S.O.)
Journal: CA A Cancer Journal for Clinicians (1971)

After careful study of the literature and other information available to it, the American Cancer Society does not have evidence that treatment with Haematoxylon dissolved in Dimethyl sulfoxide (D.M.S.O.) results in objec tive benefit in the treatment of cancer in human beings.The following is a summary of in formation on Haematoxylon Dissolved in Dimethylsulfoxide (D.M.S.
The latest victim of tobacco trade sanctions
Authors: P Vateesatokit
Journal: JAMA (1990)

When American colleagues visit me here in Bangkok, beyond the famous golden palaces and ancient temples, they see a modern city with its share of tall buildings, well-heeled businessmen, fancy boutiques, exclusive restaurants, and world-class hotels. This is deceptive. Thailand is an impoverished and underdeveloped agricultural country. Here construction workers labor 7 days a week earning $3.50 a day. Only 6 years of education are required. Thirty percent of Thai people who become ill enough to require medical attention never receive it. There are no motor vehicle emissions control testing or drunk driving laws so the air on a sunny day is a foul leaden black and accidents are the country's number one cause of death. Thai people have been smoking cigarettes for some time, and the number of tobacco-associated illnesses is accelerating. In 1987, the estimated incidence and prevalence rates of coronary heart disease were 10 to 49 and
11 Treatment of paediatric rheumatic diseases
Journal: Annals of the Rheumatic Diseases (2000)

disease, and a repeated pulmonary HRCT after 12 months showed a further progression of pulmonary fibrosis.Conclusion-Autologous PBSC transplantation associated with Campath-1g treatment was safe and well tolerated in all patients and resulted in marked and sustained clinical improvement in two of the three patients.11 Treatment of paediatric rheumatic diseases 11.
Abstract 237: PRMT1-p53-Slug Axis Regulates Epicardial EMT and Ventricular Development
Authors: Olan Jackson-Weaver, Jian Wu, Yongchao Gou, Yibu Chen, Meng Li, Henry Sucov, Jian Xu
Journal: Circulation Research (2017)

Rationale: Epicardial epithelial-to-mesenchymal trasition (EMT) is a vital process in embryonic heart development. During EMT, epicardial cells acquire migratory and invasive properties, and differentiate into new cell types, including cardiac fibroblasts and coronary smooth muscle cells. Non-histone protein methylation is an emerging modulator of cell signaling. We have recently established a role for protein arginine methyltransferase-1 (PRMT1) in TGF-β-induced EMT in cultured cells. Objective: To determine the role of PRMT1 in epicardial EMT. Methods and Results: We investigated the role of PRMT1 in epicardial EMT in mouse epicardial cells. Embryonic day 9.5 (E9.5) tamoxifen administration of WT1-Cre ERT ;PRMT1 fl/fl ;ROSA-YFP fl/fl mouse embryos was used to delete PRMT1 in the epicardium. Epicardial PRMT1 deletion led to reduced epicardial migration into the myocardium, a thinner compact myocardial layer, and dilated coronary blood vessels at E15.5. Using the epicardial cell line MEC1, we found that PRMT1 siRNA prevented the increase in mesenchymal proteins Slug and Fibronectin and the decrease in epithelial protein E-Cadherin during TGF-β treatment-induced EMT. PRMT1 siRNA also reduced the migration and invasion of MEC1 cells. We further identified that PRMT1 siRNA also increased the expression of p53, a key regulator of the Slug degradation pathway. PRMT1 siRNA increases p53 expression by decreasing p53 degradation, and shifted p53 localization to the cytoplasm. In vitro methylation assays further demonstrated that PRMT1 methylates p53. Knockdown of p53 increased Slug levels and enhanced EMT, establishing p53 as a regulator of epicardial EMT through controlling Slug expression. Furthermore, RNAseq experiments in MEC1 cells demonstrated that 40% (545/1,351) of TGF-β-induced transcriptional changes were prevented by PRMT1 siRNA. Furthermore, when p53 and PRMT1 were simultaneously knocked down, TGF-β induced transcriptional control of 37% (201/545) of these PRMT1-dependent genes was restored. Conclusions: The PRMT1-p53-Slug pathway is necessary for epicardial EMT in cultured MEC1 cells as well as in the epicardium in vivo . Epicardial PRMT1 is required for the development of compact myocardium and coronary blood vessels.